AdipoPharma LLC
AdipoPharma SAS is a French biotech company dedicated to understanding the role of adipocyte cells in diabetes, focusing on lipid biosynthesis and whole-body lipid homeostasis. The company aims to develop innovative treatments, including their first-in-class therapeutic peptide PATAS, which is set to enter clinical trials in 2025. Their mission is to create safe and effective therapies to address insulin resistance, type 2 diabetes, and related metabolic dysfunctions.
Industries
Nr. of Employees
small (1-50)
AdipoPharma LLC
Nextmed, Bâtiment eXplora (Bureau A203), 2 rue Marie Hamm, 67000 Strasbourg, France
Products
PATAS (therapeutic peptide candidate)
A first-in-class adipocyte-targeted therapeutic peptide candidate developed to restore healthy adipocyte lipid biosynthesis and address insulin resistance, type 2 diabetes and associated comorbidities; reported to reduce ceramides and improve metabolic parameters in preclinical studies and planned to enter clinical trials in 2025.
PATAS (therapeutic peptide candidate)
A first-in-class adipocyte-targeted therapeutic peptide candidate developed to restore healthy adipocyte lipid biosynthesis and address insulin resistance, type 2 diabetes and associated comorbidities; reported to reduce ceramides and improve metabolic parameters in preclinical studies and planned to enter clinical trials in 2025.
Services
End-to-end internal research and development focused on adipocyte biology, from target discovery through preclinical proof-of-concept for peptide therapeutics; includes collaborative research partnerships.
End-to-end internal research and development focused on adipocyte biology, from target discovery through preclinical proof-of-concept for peptide therapeutics; includes collaborative research partnerships.
Expertise Areas
- Adipocyte biology and metabolism
- Therapeutic peptide development
- Preclinical pharmacology and in vivo efficacy
- Lipidomics and metabolic biomarker discovery
Key Technologies
- Therapeutic peptides
- Genetic analysis of rare disease
- In vivo metabolic disease models
- Lipidomics (ceramide quantification)
News & Updates
AdipoPharma secured funding to initiate clinical trials for their innovative drug targeting insulin resistance.
AdipoPharma has secured funding to start clinical trials for their groundbreaking diabetes drug.
A feature on AdipoPharma highlighting their innovative approach to diabetes treatment.
An article about AdipoPharma's expansion and their promising molecule.
Funding round success for AdipoPharma's diabetes medication.
AdipoPharma has secured Series A funding to advance their innovative drug for diabetes treatment.
AdipoPharma secured funding to initiate clinical trials for their innovative drug targeting insulin resistance.
AdipoPharma has secured funding to start clinical trials for their groundbreaking diabetes drug.
A feature on AdipoPharma highlighting their innovative approach to diabetes treatment.
An article about AdipoPharma's expansion and their promising molecule.
Funding round success for AdipoPharma's diabetes medication.
AdipoPharma has secured Series A funding to advance their innovative drug for diabetes treatment.